Johnson & Johnson (JNJ) is a U.S.-listed healthcare stock, not an exchange-traded fund. Because it carries broad sell-side coverage, the central target is analyst-derived. Reviewing 17 recent, attributable targets — excluding stale or duplicate entries — the figures range from about $250 to $320. The arithmetic mean is approximately $283, which I round to a central target of $280 for this article. Independent trackers point to a similar picture: one major aggregator reports an average target near $279, while others range from roughly $276 to $291, depending on the analyst count and cutoff date.
Views are constructive but not uniform. The most bullish calls include UBS, which assumed coverage with a Buy and a $320 target, and HSBC, which raised its target to $320. Citi lifted its target to $303 and Scotiabank holds a $305 Buy. Near the middle, Morgan Stanley (Overweight) reiterated $294, while Guggenheim and Wells Fargo carry targets around $287. More cautious voices sit lower: Bank of America analyst Jason Gerberry reiterated a Neutral (Hold) stance while trimming his target to $275, and JPMorgan maintained a Neutral rating at $285. The wide dispersion is driven by differing assumptions about MedTech growth, the talc overhang, and how much multiple the market should pay for the pharmaceutical pipeline.
At a latest closing price near $253.79, JNJ would need to advance roughly 10% to reach $280. By any standard, that is a modest move for a large-cap equity over a research horizon, and it is well inside the stock's 52-week range of roughly $184.66 to $281.07. The shares have already traded near the $280 level in the past year, meaning the target is not a stretch on a purely technical basis.
Fundamentally, the path is plausible but not guaranteed. The company reported third-quarter results that Bank of America characterized as "okay," with revenue in line and EPS (earnings per share) modestly ahead of consensus. Innovative Medicines grew about 7.9% operationally, led by oncology and neuroscience, while MedTech rose only about 2.5%, pressured by Abiomed, value-based pricing, and geopolitical disruptions. Consensus 2026 revenue expectations sit near $101 billion, with forward EPS around $11.60, supporting a forward P/E (price-to-earnings) multiple near 22 to 23 times.
The 52-week high near $281 represents the clearest nearby resistance level, essentially coinciding with the $280 central target, so a decisive break above it would be a meaningful signal. On the downside, the $184.66 52-week low marks major structural support, with an intermediate band around the $250 area where several cautious targets cluster. The stock's long-term trend has been upward over the past year, but the current price sits just below the prior high, suggesting the target is a test of the established ceiling rather than a breakout into uncharted territory.
Analyst price targets generally reflect a research horizon of approximately 12 months, though individual firms may differ, and no single target should be read as a precise forecast. Investors should watch quarterly earnings and guidance, particularly the trajectory of MedTech versus Innovative Medicines, updates on the talc litigation, new pipeline data for oncology and immunology assets, and any further analyst revisions. Changes in interest rates and healthcare-sector sentiment can also shift the valuation multiple that underpins the target.
Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. Rather than replacing fundamental research, the tool helps traders discover opportunities, monitor existing positions, and spot shifting trends more efficiently. For investors tracking whether JNJ can sustain momentum toward its price target, combining these automated signals with traditional research can provide a more timely view of market structure.
The $280 central target reflects the arithmetic mean of 17 recent analyst price targets, roughly $283 before rounding, and requires only about a 10% advance from the latest price near $253.79. The case for reaching it rests on durable pharmaceutical growth, a strong balance sheet, and broadly constructive analyst revisions, while the case against it hinges on MedTech weakness, talc litigation, and a valuation that some see as already fair. With targets spread from $250 to $320, the disagreement is genuine, and no outcome is assured. Investors should weigh the pipeline's momentum against the litigation and segment-specific headwinds before drawing conclusions.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, JNJ has been loosely correlated with ABBV. These tickers have moved in lockstep 51% of the time. This A.I.-generated data suggests there is some statistical probability that if JNJ jumps, then ABBV could also see price increases.